IS8300A - Peptíð og efnasambönd sem bindast viðtökum blóðflagnavaka - Google Patents

Peptíð og efnasambönd sem bindast viðtökum blóðflagnavaka

Info

Publication number
IS8300A
IS8300A IS8300A IS8300A IS8300A IS 8300 A IS8300 A IS 8300A IS 8300 A IS8300 A IS 8300A IS 8300 A IS8300 A IS 8300A IS 8300 A IS8300 A IS 8300A
Authority
IS
Iceland
Prior art keywords
peptides
bind
compounds
platelet receptors
platelet
Prior art date
Application number
IS8300A
Other languages
English (en)
Inventor
R. Macdonald Brian
Kenneth Weis Jeffrey
John Yurkow Edward
Original Assignee
Ortho-Mcneil Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8300(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho-Mcneil Pharmaceuticals, Inc. filed Critical Ortho-Mcneil Pharmaceuticals, Inc.
Publication of IS8300A publication Critical patent/IS8300A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
IS8300A 2003-08-28 2006-02-14 Peptíð og efnasambönd sem bindast viðtökum blóðflagnavaka IS8300A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Publications (1)

Publication Number Publication Date
IS8300A true IS8300A (is) 2006-02-14

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8300A IS8300A (is) 2003-08-28 2006-02-14 Peptíð og efnasambönd sem bindast viðtökum blóðflagnavaka

Country Status (33)

Country Link
US (1) US7576056B2 (is)
EP (1) EP1675606B1 (is)
JP (1) JP4848277B2 (is)
KR (2) KR20120078742A (is)
CN (2) CN102241742B (is)
AR (1) AR045530A1 (is)
AU (1) AU2004270656B2 (is)
BR (1) BRPI0414008B8 (is)
CA (1) CA2537421C (is)
CY (1) CY1118965T1 (is)
DK (1) DK1675606T3 (is)
EA (1) EA009286B1 (is)
EC (1) ECSP066396A (is)
ES (1) ES2626107T3 (is)
HK (1) HK1096873A1 (is)
HR (1) HRP20170810T1 (is)
HU (1) HUE032370T2 (is)
IL (1) IL173965A (is)
IS (1) IS8300A (is)
LT (1) LT1675606T (is)
ME (1) ME00313B (is)
MX (1) MXPA06002292A (is)
NO (1) NO344233B1 (is)
NZ (1) NZ545455A (is)
PL (1) PL1675606T3 (is)
PT (1) PT1675606T (is)
RS (2) RS20060141A (is)
SG (1) SG131110A1 (is)
SI (1) SI1675606T1 (is)
TW (1) TWI348375B (is)
UA (1) UA82710C2 (is)
WO (1) WO2005023834A2 (is)
ZA (1) ZA200602495B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
HU228582B1 (en) 1998-10-23 2013-04-29 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
ES2462916T3 (es) 2002-09-18 2014-05-26 Janssen Pharmaceuticals, Inc. Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
SI1675606T1 (sl) 2003-08-28 2017-07-31 Janssen Pharmaceuticals, Inc. Peptidi in spojine, ki se vežejo na trombopoietinske receptorje
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
AU2007208226A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
JP2009526841A (ja) * 2006-02-14 2009-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｐｏペプチド化合物及び薬学的組成物の貧血症の処置における使用
MY151332A (en) * 2006-02-14 2014-05-15 Janssen Pharmaceutica Nv Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
MX2010013281A (es) * 2008-06-03 2010-12-21 Janssen Pharmaceutica Nv Peptido mimetico de trombopoyetina para prevenir trastornos hematologicos asociados con el tratamiento del cancer.
EP2725053B1 (en) 2011-06-23 2016-02-10 Shimadzu Corporation Branched amphipathic block polymer and molecular aggregate and drug delivery system using same
EP3658191A1 (en) * 2017-07-26 2020-06-03 Janssen Pharmaceutica NV Methods of protecting vascular integrity induced by targeted radiation therapy
CA3127378A1 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
MA54821A (fr) * 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
MA54820A (fr) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv Méthodes d'atténuation d'une lésion hépatique et de promotion d'une hypertrophie hépatique, de régénération du foie et de prise de greffe de cellules hépatiques conjointement avec des traitements par radiothérapie et/ou radiomimétiques
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
PT644771E (pt) 1992-06-11 2002-12-31 Alkermes Inc Sistema de entrega da droga eritropoietina
JP3401005B2 (ja) 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
SG79882A1 (en) 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
WO1995021626A1 (en) 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
CN1148408A (zh) 1994-02-14 1997-04-23 津莫吉尼蒂克斯公司 血细胞生成蛋白及其制造材料和方法
EP0755263A4 (en) 1994-03-31 2005-02-09 Amgen Inc COMPOUNDS AND METHODS FOR STIMULATING MEGAKARYOCYTE GROWTH AND THEIR DIFFERENTIATION
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
KR100376150B1 (ko) * 1994-11-04 2003-11-01 산텐 세이야꾸 가부시키가이샤 히드록시기를함유하는1,3-디알킬우레아유도체
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1996017062A1 (en) 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
CA2194070A1 (en) 1995-04-26 1996-10-31 Haruhiko Yokoi Novel polypeptides
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
CN1315870C (zh) 1995-06-07 2007-05-16 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
EP1223944B1 (en) 1999-09-24 2007-01-03 SmithKline Beecham Corporation Thrombopoietin mimetics
RU2276156C2 (ru) * 2000-12-22 2006-05-10 Ипсен Мануфэкчуринг Ирленд Лимитед Способ синтеза пептида, содержащего остаток триптофана
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
ES2462916T3 (es) 2002-09-18 2014-05-26 Janssen Pharmaceuticals, Inc. Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
SI1675606T1 (sl) 2003-08-28 2017-07-31 Janssen Pharmaceuticals, Inc. Peptidi in spojine, ki se vežejo na trombopoietinske receptorje

Also Published As

Publication number Publication date
HRP20170810T1 (hr) 2017-08-11
CY1118965T1 (el) 2018-01-10
ECSP066396A (es) 2006-08-30
HUE032370T2 (en) 2017-09-28
RS56387B1 (sr) 2017-12-29
CA2537421C (en) 2011-09-27
CN1871022B (zh) 2011-07-06
CN102241742B (zh) 2014-04-02
WO2005023834A3 (en) 2005-05-06
PL1675606T3 (pl) 2017-08-31
EP1675606B1 (en) 2017-04-05
BRPI0414008A (pt) 2006-10-24
EA009286B1 (ru) 2007-12-28
ES2626107T3 (es) 2017-07-24
CA2537421A1 (en) 2005-03-17
US20050137133A1 (en) 2005-06-23
TWI348375B (en) 2011-09-11
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30
AR045530A1 (es) 2005-11-02
AU2004270656A1 (en) 2005-03-17
CN102241742A (zh) 2011-11-16
ZA200602495B (en) 2007-06-27
LT1675606T (lt) 2017-11-10
KR101183875B1 (ko) 2012-09-27
PT1675606T (pt) 2017-05-22
JP4848277B2 (ja) 2011-12-28
IL173965A (en) 2015-10-29
EA200600477A1 (ru) 2007-02-27
CN1871022A (zh) 2006-11-29
KR20120078742A (ko) 2012-07-10
SI1675606T1 (sl) 2017-07-31
NZ545455A (en) 2009-02-28
US7576056B2 (en) 2009-08-18
TW200517103A (en) 2005-06-01
KR20070017942A (ko) 2007-02-13
EP1675606A2 (en) 2006-07-05
NO20061346L (no) 2006-05-22
HK1096873A1 (en) 2007-06-15
UA82710C2 (uk) 2008-05-12
IL173965A0 (en) 2006-07-05
ME00313B (me) 2011-05-10
BRPI0414008B8 (pt) 2021-05-25
JP2007504132A (ja) 2007-03-01
RS20060141A (en) 2008-08-07
SG131110A1 (en) 2007-04-26
NO344233B1 (no) 2019-10-14
MEP48508A (en) 2011-02-10
BRPI0414008B1 (pt) 2018-05-15
AU2004270656B2 (en) 2011-03-10
MXPA06002292A (es) 2006-09-04
WO2005023834A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
IS8300A (is) Peptíð og efnasambönd sem bindast viðtökum blóðflagnavaka
IS8160A (is) N-asýlköfnunarefnisheteróhringir sem bindlar oxunarkornfjölgunarvirkjaðra viðtaka
CY2012003I1 (el) Αντισωματα που συνδεονται ανοσοειδικως προς blys
DE50306910D1 (de) Dreidimensionale knotenstruktur
NO20055186D0 (no) Fjellbolt
IS2683B (is) Ný peptíð sem bindast rauðkornavakaviðtakanum
AU2002364954A8 (en) Antibodies that immunospecifically bind to blys
ATE427303T1 (de) Benzoimidazolverbindungen
DE602004018656D1 (de) Verbundrohr
DE602004022805D1 (de) Quinuclidin-derivate bindend an muscarin-m3-rezeptoren
ATE491774T2 (de) Benzinzusammensetzung
AU2003234706A8 (en) Antibodies that specifically bind to tl5
AU2003218456A8 (en) Antibodies that specifically bind to gmad
AU2003240822A8 (en) Antibodies that specifically bind to neurokinin b
FR2859943B1 (fr) Structure composite
EP1633316A4 (en) ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
DE50307193D1 (de) Verpackungsbeutel
AU2003259835A8 (en) Antibodies that immunospecifically bind to trail receptors
FR2842503B1 (fr) Banderoleuse
AU2003228483A8 (en) Antibodies that specifically bind to tr2
DE502004007589D1 (de) Spitzkopfnadel
NO20045094D0 (no) Emballasje
FI20041361A (fi) Pakkausmateriaalit
ATA20132003A (de) Sorptionselement
ATA14862003A (de) Adsorbereinrichtung